Sumatriptan/Naproxen Sodium: A Review in Migraine
Abstract Sumatriptan/naproxen sodium ($ Treximet^{®} $) is a fixed-dose combination of a serotonin 5-$ HT_{1B/1D} $ receptor agonist (sumatriptan) and an NSAID (naproxen sodium), approved in the USA for the acute treatment of migraine with or without aura in adolescents and adults. In a randomized, phase 3 trial in adolescents, significantly more sumatriptan/naproxen sodium than placebo recipients were pain-free at 2 h. Similarly, in a pair of randomized phase 3 trials in adults, significantly more sumatriptan/naproxen sodium than placebo recipients had relief from migraine symptoms at 2 h, and the combination was more effective than individual components in terms of sustained (2–24 h) pain-free response rate. Sumatriptan/naproxen sodium was generally well tolerated, with ≤11 % of adolescents and ≤22 % of adults reporting treatment-related adverse events in the key clinical trials. The most common adverse reactions were nasopharyngitis, hot flushes and muscle tightness in adolescents, and dizziness, pain or pressure sensations, nausea, somnolence, dry mouth, dyspepsia and paraesthesia in adults. Based on current data, sumatriptan/naproxen sodium is a useful option for the acute treatment of migraine in adolescents and adults. The fixed-dose combination may reduce pill burden and improve adherence in some patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Drugs - 76(2015), 1 vom: 01. Dez., Seite 111-121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Syed, Yahiya Y. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s40265-015-0521-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR03321672X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR03321672X | ||
| 003 | DE-627 | ||
| 005 | 20230519195037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40265-015-0521-8 |2 doi | |
| 035 | |a (DE-627)SPR03321672X | ||
| 035 | |a (SPR)s40265-015-0521-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Syed, Yahiya Y. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sumatriptan/Naproxen Sodium: A Review in Migraine |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Sumatriptan/naproxen sodium ($ Treximet^{®} $) is a fixed-dose combination of a serotonin 5-$ HT_{1B/1D} $ receptor agonist (sumatriptan) and an NSAID (naproxen sodium), approved in the USA for the acute treatment of migraine with or without aura in adolescents and adults. In a randomized, phase 3 trial in adolescents, significantly more sumatriptan/naproxen sodium than placebo recipients were pain-free at 2 h. Similarly, in a pair of randomized phase 3 trials in adults, significantly more sumatriptan/naproxen sodium than placebo recipients had relief from migraine symptoms at 2 h, and the combination was more effective than individual components in terms of sustained (2–24 h) pain-free response rate. Sumatriptan/naproxen sodium was generally well tolerated, with ≤11 % of adolescents and ≤22 % of adults reporting treatment-related adverse events in the key clinical trials. The most common adverse reactions were nasopharyngitis, hot flushes and muscle tightness in adolescents, and dizziness, pain or pressure sensations, nausea, somnolence, dry mouth, dyspepsia and paraesthesia in adults. Based on current data, sumatriptan/naproxen sodium is a useful option for the acute treatment of migraine in adolescents and adults. The fixed-dose combination may reduce pill burden and improve adherence in some patients. | ||
| 650 | 4 | |a Migraine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Naproxen |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sumatriptan |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Naproxen Sodium |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Zolmitriptan |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d Berlin [u.a.] : Springer, 1971 |g 76(2015), 1 vom: 01. Dez., Seite 111-121 |w (DE-627)SPR033129762 |w (DE-600)2021165-X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2015 |g number:1 |g day:01 |g month:12 |g pages:111-121 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40265-015-0521-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 76 |j 2015 |e 1 |b 01 |c 12 |h 111-121 | ||